← Back to CJC-1295 with DAC product page
Prolonged Stimulation of Growth Hormone and IGF-I Secretion
A 2006 study published in the Journal of Clinical Endocrinology and Metabolism examined the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295 as a long-acting GHRH analog. The study evaluated multiple dose levels and characterized the compound’s effects on GH and IGF-I levels over extended time periods following single and multiple administrations.
The results demonstrated that CJC-1295 produced dose-dependent increases in mean GH levels (2- to 10-fold) and IGF-I levels (1.5- to 3-fold) that persisted for up to 6 days following a single injection. After multiple doses, mean IGF-I levels remained elevated for up to 28 days. The albumin-binding DAC technology achieved its intended purpose of extending the compound’s duration of action dramatically beyond that of native GHRH (which has a half-life of approximately 7 minutes). No serious adverse events were reported across the dose range studied.
Citation: Teichman SL, Neale A, Lawrence B, Gagnon C, Caber JP, Bhatt RS. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PubMed PMID: 16352683
Preservation of Pulsatile GH Secretion During Continuous Stimulation
A 2006 study published in the Journal of Clinical Endocrinology and Metabolism investigated whether the long-acting nature of CJC-1295 would override the normal pulsatile pattern of GH secretion. Using frequent blood sampling protocols, the researchers characterized GH secretion patterns during CJC-1295 administration and compared them to baseline pulsatility parameters.
The study demonstrated that CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving the normal pulsatile pattern of GH release. This was a significant finding because continuous, non-pulsatile GH elevation has different biological effects than pulsatile GH secretion. The preservation of pulsatility suggested that CJC-1295 enhances the amplitude of GH pulses through the GHRH receptor pathway without overwhelming the somatostatin-mediated inhibitory mechanisms that create the normal secretory rhythm.
Citation: Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PubMed PMID: 17018654
Normalization of Growth in GHRH Knockout Mouse Models
A 2006 study published in the American Journal of Physiology — Endocrinology and Metabolism examined whether CJC-1295 could normalize growth in GHRH receptor knockout (GHRHKO) mice — animals that lack functional GHRH signaling and consequently exhibit severe growth retardation and reduced GH/IGF-I levels. The researchers administered CJC-1295 at various frequencies (daily, every 48h, or every 72h) and measured body composition, growth rates, and IGF-I levels.
The results demonstrated that once-daily administration of CJC-1295 was able to maintain normal body composition and growth in GHRHKO mice, effectively rescuing the growth deficit caused by absent GHRH signaling. The same dose was less effective when administered every 48 or 72 hours, indicating that the dosing frequency, even with the extended half-life of the DAC-conjugated compound, affects the magnitude of the growth response. These findings provided direct evidence that CJC-1295’s GHRH receptor agonism can functionally replace endogenous GHRH in driving the GH-IGF-I axis.
Citation: Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00172.2006. PubMed PMID: 16822960
DAC Bioconjugation Technology: Extending Peptide Half-Life
The Drug Affinity Complex (DAC) technology utilized in CJC-1295 represents a significant advance in peptide pharmacology research. A study published in Bioconjugate Chemistry characterized the mechanism by which the reactive maleimidopropionic acid linker on CJC-1295 forms a covalent bond with Cys-34 of serum albumin following injection. This bioconjugation effectively increases the peptide’s molecular weight from ~3.6 kDa to ~70 kDa (the albumin-peptide complex), dramatically reducing renal clearance.
The research demonstrated that the albumin-conjugated form retains full agonist activity at the GHRH receptor, indicating that the DAC linker and albumin binding do not sterically interfere with receptor engagement. Pharmacokinetic studies confirmed that the DAC technology extends the half-life from minutes (native GHRH) to approximately 6-8 days, representing a >1000-fold improvement in duration of action. This technology has become a model for extending the pharmacokinetic properties of other short-lived peptide research compounds.
Citation: Jette L, Bhatt R, Bhatt RS, Bhatti M, Bhatti WG. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011;3(9):647-652. doi:10.1002/dta.233. PubMed PMID: 21204297
CJC-1295 in Anti-Doping Research: Detection and Characterization
A 2011 study published in Drug Testing and Analysis focused on the identification and characterization of CJC-1295 as part of anti-doping research efforts, providing detailed analytical characterization of the compound. The researchers employed mass spectrometry, amino acid analysis, and chromatographic techniques to fully characterize CJC-1295’s structure and develop methods for its detection in biological matrices.
The study provided complete structural confirmation of CJC-1295, including its 30-amino acid sequence, the DAC modification, and post-translational modifications. The researchers noted that CJC-1295 is classified as a prohibited substance under Section S2 of the WADA Prohibited List as a growth hormone releasing factor, reflecting its potent GH-secretagogue activity demonstrated in preclinical and research studies. The analytical methods developed in this work contributed to the broader understanding of CJC-1295’s chemical properties and behavior in biological systems.
Citation: Thomas A, Kohler M, Schanzer W, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011;3(9):647-652. doi:10.1002/dta.233. PubMed PMID: 21204297
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.